Risk factors for pericardial effusion in adult patients receiving allogeneic haematopoietic stem cell transplantation

被引:23
作者
Liu, Yao-Chung [1 ,2 ,3 ]
Chien, Sheng-Hsuan [2 ,3 ]
Fan, Nai-Wen [3 ,5 ]
Hu, Ming-Hung [2 ,3 ,4 ]
Gau, Jyh-Pyng [2 ,3 ]
Liu, Chia-Jen [2 ,3 ]
Yu, Yuan-Bin [2 ,3 ]
Liu, Chun-Yu [2 ,3 ]
Hsiao, Liang-Tsai [2 ,3 ]
Liu, Jin-Hwang [2 ,3 ]
Chiou, Tzeon-Jye [2 ,3 ]
Tzeng, Cheng-Hwai [2 ,3 ]
机构
[1] Taipei City Hosp, Dept Med, Yang Ming Branch, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Div Haematol & Oncol, Dept Med, Taipei 112, Taiwan
[3] Natl Yang Ming Univ, Fac Med, Taipei 112, Taiwan
[4] Cardinal Tien Hosp, Dept Med, Taipei, Taiwan
[5] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei 112, Taiwan
关键词
stem cell transplantation; pericardial effusion; cardiac tamponade; graft-versus-host disease; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; CONSTRICTIVE PERICARDITIS; CARDIAC-TAMPONADE; DIAGNOSIS; TOXICITY;
D O I
10.1111/bjh.13357
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pericardial effusion (PE) is a rare but potentially life-threatening complication for allogeneic haematopoietic stem cell transplantation (HSCT) recipients. The risk factors, aetiology, incidence and therapy are largely unclear. To investigate this issue, we reviewed 391 adult patients undergoing allogeneic HSCT between January 2003 and December 2013. Twelve out of 391 patients (31%) developed PE of moderate to large amounts, including 9 out of 12 patients (75%) identified as late-onset PE. Two out of the nine patients with late-onset PE experienced recurrent effusion. The median age at HSCT was 445years (range: 22-63years) among the 12 patients with PE and 47years in the late-onset patients. Multivariate analysis revealed that multiple transplant procedures was a significant risk factor for PE (P=0036) and a trend as risk factor in patients aged>50years (P=0066). For late-onset PE, pre-transplant age>50years (P=0032) and extensive chronic graft-versus-host disease (cGVHD) (P=0006) remained statistically significant on multivariate analysis. Currently, there are no published data exploring the risk factors for post-transplant PE in adult patients of allogeneic HSCT. Our study determined the risk factors and incidence for the post-transplant PE, especially in the late-onset group.
引用
收藏
页码:737 / 745
页数:9
相关论文
共 22 条
[1]   Pericardial effusion after pediatric hematopoietic cell transplant [J].
Aldoss, Osamah ;
Gruenstein, Daniel H. ;
Bass, John L. ;
Steinberger, Julia ;
Zhang, Yan ;
DeFor, Todd E. ;
Tolar, Jakub ;
Verneris, Michael R. ;
Orchard, Paul J. .
PEDIATRIC TRANSPLANTATION, 2013, 17 (03) :294-299
[2]   SUDDEN CARDIAC-TAMPONADE AFTER CHEMOTHERAPY FOR MARROW TRANSPLANTATION IN THALASSEMIA [J].
ANGELUCCI, E ;
MARIOTTI, E ;
LUCARELLI, G ;
BARONCIANI, D ;
CESARONI, P ;
DURAZZI, SMT ;
GALIMBERTI, M ;
GIARDINI, C ;
MURETTO, P ;
POLCHI, P ;
SGARBI, E .
LANCET, 1992, 339 (8788) :287-289
[3]   Malignant Pericardial Effusion [J].
Burazor, I. ;
Imazio, M. ;
Markel, G. ;
Adler, Y. .
CARDIOLOGY, 2013, 124 (04) :224-232
[4]   Constrictive pericarditis post allogeneic bone marrow transplant for Philadelphia-positive acute lymphoblastic leukaemia [J].
Cavet, J ;
Lennard, A ;
Gascoigne, A ;
Finney, RD ;
Lucraft, HH ;
Richardson, C ;
Taylor, PRA ;
Proctor, SJ ;
Jackson, GH .
BONE MARROW TRANSPLANTATION, 2000, 25 (05) :571-573
[5]   Diagnosis and management of chronic graft-versus-host disease [J].
Dignan, Fiona L. ;
Amrolia, Persis ;
Clark, Andrew ;
Cornish, Jacqueline ;
Jackson, Graham ;
Mahendra, Prem ;
Scarisbrick, Julia J. ;
Taylor, Peter C. ;
Shaw, Bronwen E. ;
Potter, Michael N. .
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (01) :46-61
[6]  
Ferreira David Cavalcanti, 2014, Rev. Bras. Hematol. Hemoter., V36, P159, DOI 10.5581/1516-8484.20140034
[7]   National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report [J].
Filipovich, AH ;
Weisdorf, D ;
Pavletic, S ;
Socie, G ;
Wingard, JR ;
Lee, SJ ;
Martin, P ;
Chien, J ;
Przepiorka, D ;
Couriel, D ;
Cowen, EW ;
Dinndorf, P ;
Farrell, A ;
Hartzman, R ;
Henslee-Downey, J ;
Jacobsohn, D ;
McDonald, G ;
Mittleman, B ;
Rizzo, JD ;
Robinson, M ;
Schubert, M ;
Schultz, K ;
Shulman, H ;
Turner, M ;
Vogelsang, G ;
Flowers, MED .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (12) :945-956
[8]   The EBMT risk score [J].
Gratwohl, A. .
BONE MARROW TRANSPLANTATION, 2012, 47 (06) :749-756
[9]   CARDIAC TOXICITY OF BONE-MARROW TRANSPLANTATION - PREDICTIVE VALUE OF CARDIOLOGIC EVALUATION BEFORE TRANSPLANT [J].
HERTENSTEIN, B ;
STEFANIC, M ;
SCHMEISER, T ;
SCHOLZ, M ;
GOLLER, V ;
CLAUSEN, M ;
BUNJES, D ;
WIESNETH, M ;
NOVOTNY, J ;
KOCHS, M ;
ADAM, WE ;
HEIMPEL, H ;
ARNOLD, R .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (05) :998-1004
[10]  
Krishnan GS, 2008, ANN TRANSPL, V13, P44